Less is more: The journey from maximum tolerated dose to optimal biological dose

医学 药理学 剂量-反应关系 最大耐受剂量 有效剂量(辐射) 辐射剂量 加药 临床试验 药代动力学 效力
作者
Harshith Koneti,Charanpreet Singh
出处
期刊:International journal of noncommunicable diseases [Medknow]
卷期号:11 (3): 195-197
标识
DOI:10.4103/jncd.jncd_136_26
摘要

The dose at which a drug enters clinical practice is largely determined by how it was first tested in humans. In oncology, Phase I trials are designed to establish the recommended dose for efficacy testing in Phase II. For decades, the dominant method has been the “3 + 3” design: small sequential cohorts of three patients receive escalating doses, and dose escalation proceeds until predefined dose-limiting toxicity thresholds are exceeded.[1] The highest dose at which fewer than one-third of patients experience dose-limiting toxicity is defined as the maximum tolerated dose (MTD), and this dose (or one level below it) becomes the recommended Phase II dose (RP2D). The underlying logic is borrowed from cytotoxic chemotherapy: more drug kills more cancer cells, and the limiting factor is what the patient can tolerate. This logic, however, does not apply to immune checkpoint inhibitors. Anti-PD-1 and anti-PD-L1 antibodies work by releasing a brake on the immune system, not by directly killing tumour cells, and their pharmacodynamic effect saturates at doses well below what patients can tolerate. In the pivotal phase I study of pembrolizumab (KEYNOTE-001), doses of 1, 3, and 10 mg/kg were tested; no dose-limiting toxicities were observed at any level, and no MTD was identified.[2] Efficacy and safety data were indistinguishable across the tested range, with a flat exposure-response relationship spanning a fivefold dose difference. Despite this, the approved dose was set at 200 mg Q3W, chosen despite the absence of evidence demonstrating superior efficacy compared with lower doses. Nivolumab, atezolizumab, durvalumab, and ipilimumab followed a similar trajectory: no MTD was reached, yet a high dose was carried forward.[2] The result is a class of drugs approved at doses that may exceed the minimum dose required for maximal biological activity, and priced accordingly. Receptor occupancy data in melanoma show that the therapeutic threshold of 70–75% PD-1 saturation is reached at nivolumab doses one-tenth of the approved amount.[3] A 2024 pharmacokinetic analysis confirmed that Cmax, AUC, response rates, and toxicity are statistically indistinguishable between a 40 mg flat dose of nivolumab and the 240 mg standard.[4] The MTD framework, conceived for a different class of drug, has produced approved doses that are not wrong in a safety sense, but are suboptimal from an access perspective. The consequences are not abstract. Of 15,674 patients who needed immune checkpoint therapy for thoracic and head and neck cancers at a single Indian tertiary centre, only 444 (fewer than 3%) received it.[5] The barrier was not regulatory delay or physician unfamiliarity. It was price. Pembrolizumab, the world’s highest-revenue drug in 2023 and approved in over 40 indications, is also among the least accessible to populations that carry the greatest cancer burden.[5] The concept of optimal biological dose (OBD), defined as the lowest dose that achieves full pharmacodynamic effect while maintaining clinical efficacy and minimising toxicity and cost, has existed in the literature for years. It has not been systematically pursued. A growing body of Indian investigator-initiated trials is now making that pursuit consequential. Evidence Across Disease Settings Classical Hodgkin lymphoma may be the most compelling proof of concept. Near-universal 9p24.1 amplification drives constitutive PD-L1 overexpression on Reed-Sternberg cells, making this disease unusually responsive to PD-1 blockade and, in theory, receptive to lower doses than solid tumours. Available data support this hypothesis across multiple settings: a matched cohort study showed identical five-year outcomes with nivolumab 40 mg versus the standard dose at a median follow-up exceeding five years;[6] salvage data combining the same low dose with conventional chemotherapy yielded complete response rates above 90%;[7] and a phase 2 chemo-free trial in which 40 mg achieved complete PD-1 receptor occupancy sustained well beyond the standard dosing interval [Table 1].[8]Table 1: Summary of key evidence supporting low-dose immunotherapy across disease settingsThe evidence for solid tumours spans metastatic, locally advanced, and neoadjuvant settings. The DELII trial, a randomised phase II study of 500 patients with relapsed or refractory solid tumours, reported a survival benefit with nivolumab 20 mg Q2W over chemotherapy, at roughly one-twelfth the standard cost.[9] In recurrent or metastatic head and neck cancer, the same low dose, when added to oral metronomic chemotherapy, numerically outperformed the 240 mg standard from CheckMate 141.[10] In the neoadjuvant setting, low-dose nivolumab combined with standard chemotherapy is yielding pathological complete response rates and event-free survival figures comparable with international standard-dose benchmarks.[10-13] The results of most of these studies have been presented as conference abstracts, and the full peer-reviewed manuscripts remain eagerly awaited. The principle extends beyond PD-1 blockade. For teclistamab, a bispecific T-cell engager targeting BCMA in multiple myeloma, regulators have formally approved dose de-escalation from weekly to fortnightly dosing for patients achieving deep responses, halving infection rates without compromising response durability.[14,15] Real-world data from over 600 patients confirm this shift in routine practice.[16,17] Even horse anti-thymocyte globulin, a pharmacologically blunt polyclonal preparation, shows comparable response rates and five-year survival at 25 mg/kg/day compared with the standard 40 mg/kg/day in severe aplastic anaemia.[18] What Should Follow This is not a call to revise global guidelines on the strength of phase II trials and retrospective cohorts. It is a call to change the question being asked. Drug development has centred on maximum tolerated dose for decades; it has not, as a discipline, seriously pursued optimal biological dose. Although emerging evidence supports lower-dose strategies, definitive confirmation through adequately powered phase III non-inferiority studies remains necessary before widespread adoption across all indications. The recent FDA Project Optimus initiative reflects growing regulatory recognition that dose selection based solely on maximum tolerated dose may be inadequate for targeted and immune therapies. Regulatory agencies need clearer pathways to approve dose de-escalation of licensed drugs, a pathway radiotherapy has pursued systematically for twenty years and that the teclistamab experience shows is achievable for immunotherapy. India has assembled, across multiple institutions and disease types, a rigorous and internally consistent body of evidence showing that effective immunotherapy need not be expensive. Whether the global oncology community chooses to act on it is no longer a scientific question. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
优美薯片发布了新的文献求助10
1秒前
wanci的应助被ss采纳,获得10
1秒前
1秒前
1秒前
11完成签到,获得积分10
1秒前
1秒前
一个小短发完成签到 ,获得积分10
1秒前
1秒前
尊敬的小凡完成签到,获得积分10
2秒前
古木完成签到,获得积分20
2秒前
2秒前
Jyu的应助被Aurora采纳,获得10
2秒前
httpyg完成签到,获得积分10
3秒前
stan完成签到,获得积分20
3秒前
3秒前
4秒前
内向秋寒完成签到,获得积分10
4秒前
科研劝退完成签到,获得积分10
5秒前
5秒前
017发布了新的文献求助10
5秒前
5秒前
5秒前
lala完成签到,获得积分10
5秒前
5秒前
哈哈哈啊完成签到,获得积分10
5秒前
moooj发布了新的文献求助10
5秒前
Wendy完成签到,获得积分10
5秒前
脑洞疼的应助被梨花诗采纳,获得10
6秒前
实验室发布了新的文献求助10
6秒前
6秒前
科研通AI6.2的应助被kakavia采纳,获得10
6秒前
卢卡雷欢发布了新的文献求助10
6秒前
科研通AI6.2的应助被huanxian1995采纳,获得30
6秒前
大反应釜完成签到,获得积分10
7秒前
Joy发布了新的文献求助10
7秒前
棕棕完成签到,获得积分20
7秒前
mm发布了新的文献求助10
7秒前
7秒前
你家吗完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8161857
求助须知:如何正确求助?哪些是违规求助? 9556272
关于积分的说明 21733778
捐赠科研通 7751772
什么是DOI,文献DOI怎么找? 3427616
关于科研通互助平台的介绍 2552632
邀请新用户注册赠送积分活动 2472079